Brain Cancer Treatment Advances: Surgery, Radiation Therapy, Systemic Therapy & Clinical Trials
Why It Matters
Integrating precision surgery, advanced radiation, and targeted systemic therapies accelerates personalized care, potentially extending survival and preserving function for brain tumor patients.
Key Takeaways
- •Maximal safe resection remains the cornerstone of glioma treatment.
- •Intraoperative MRI and fluorescence improve tumor removal accuracy.
- •Real‑time AI predicts tumor genetics within minutes during surgery.
- •Proton and gamma‑knife therapies offer precise, lower‑toxicity radiation options.
- •Combining radiation with targeted drugs and immunotherapy enhances disease control.
Summary
The NYU Brain and Spine Tumor Center hosted a webinar highlighting the latest advances in brain cancer treatment, spanning surgical innovations, radiation techniques, systemic therapies, and ongoing clinical trials. Leading physicians Dr. Dan Orer and Dr. Jonathan Yang outlined how multidisciplinary care is evolving to improve outcomes for glioma patients.
Dr. Orer emphasized that maximal safe resection remains the foundation of therapy, noting that higher percentages of tumor removal correlate with longer survival. He described a suite of intra‑operative tools—real‑time MRI, ultrasound navigation, fluorescence labeling, and functional mapping—that together allow surgeons to see both the brain’s anatomy and the tumor’s microscopic extensions. Recent AI‑driven imaging can forecast genetic alterations such as IDH status within minutes, and ultra‑rapid droplet digital PCR promises intra‑operative sequencing to guide resection margins.
Dr. Yang focused on radiation oncology, explaining that photon‑based IMRT, Gamma Knife, and proton therapy each deliver high‑energy beams with increasing precision and reduced collateral damage. He cited historical data from the 1970s establishing radiation as the backbone of post‑surgical control, and outlined current strategies that pair radiation with smart drug combinations and immunomodulatory agents to boost tumor kill rates. The center’s in‑house proton facility in New Jersey exemplifies its commitment to cutting‑edge delivery.
Together, these advances suggest a future where glioma patients receive highly personalized, multimodal treatment that maximizes tumor eradication while preserving neurological function. Institutions that adopt these technologies and collaborative trial designs may see measurable gains in progression‑free survival and quality of life, reshaping standards of care across neuro‑oncology.
Comments
Want to join the conversation?
Loading comments...